Market Cap
$253.5M
CAMP
Camp4 Therapeutics Corp
$3.84 ▼ -0.13%
Prev close $3.84Market cap$253.5M
ConsensusStrong Buy
12-mo target$9.83 (+156.4%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)High Impact Filing (8/10)11 New Institutional Positions4 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CAMP right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
42 funds
Inst. Value
$104.5M
Inst. Activity
11 buys / 4 sells
Insider Activity
$5.0M buy / $2.5M sell
Insider Net $
$2.5M
SEC Reports
10
Press Releases
3
Price chart 30d +0.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 10, 2026 Press Aug 13, 2026 SEC
CAMP4 received MHRA authorization to include UK sites in its global Phase 1/2 trial of CMP-002 for SYNGAP1-related disor
Impact 4/10
Sep 10, 2026 fda
Sep 2, 2026 SEC CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAM
Camp4 Therapeutics Corp (CAMP) insider trading cluster shows a mixed pattern: Director Andrew Schwab sold 400,000 shares
CLUSTER — Impact 3/10
Aug 31, 2026 Insider
Gold Kelly bought 10,000 shares
Chief Financial Officer @ $3.96 ($39.6K)
Aug 27, 2026 Insider
Schwab Andrew J. sold 400,000 shares
Director @ $4.04 ($1.6M)
Aug 24, 2026 Insider
Aug 22, 2026 SEC Schwab Andrew J. sold 10 shares
Director @ $4.50 ($45.00)
Two Camp4 insiders — Director Andrew Schwab and CSO Daniel Tardiff — sold a combined $223K in open-market sales on Augus
CLUSTER — Impact 4/10
Camp4 Therapeutics Corp's S-3 shelf registration statement (File No. 333-298067) was declared effective by the SEC on Au
EFFECT — Impact 3/10
Analyst ratings buy % +10.8%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 29, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
| Aug 14, 2026 | Piper Sandler | REITERATE | Overweight | 54% |
| Jun 16, 2026 | JP Morgan | UPGRADE | Overweight | 55% |
| Jun 10, 2026 | Chardan Capital | INITIATE | Buy | 49% |
| Apr 14, 2026 | Rodman & Renshaw | INITIATE | Buy | 39% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| May 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Apr 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Feb 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% |
Price targets
Where 6 covering analysts think CAMP trades over the next 12 months.
$9.83 +156.4% upside Strong Buy
Current$3.84 Low$6.00 Median$8.50 High$15.00 6 analysts
$6.00$15.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 3 bullish, 1 bearish, 1 mixed, 5 neutral · avg impact 4.6/10.Plus 3 press releases.
NEUTRALCLUSTER3/10
Camp4 Therapeutics Corp (CAMP) insider trading cluster shows a mixed pattern: Director Andrew Schwab
Sep 2, 2026
BEARISHCLUSTER4/10
Two Camp4 insiders — Director Andrew Schwab and CSO Daniel Tardiff — sold a combined $223K in open-m
Aug 22, 2026
NEUTRALEFFECT3/10
Camp4 Therapeutics Corp's S-3 shelf registration statement (File No. 333-298067) was declared effect
Aug 13, 2026
BULLISHCLUSTER8/10
A powerful insider buying cluster at Camp4 Therapeutics: 5AM Partners VI (a 10% owner) made a $4.86M
Aug 6, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 10, 2026
fda
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human
Sep 8, 2026
other
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical compa
Sep 8, 2026
ftd
FTD: CAMP — 412,735 shares ($1.8M) failed to deliver
Settlement: 20260908, Price: $4.41, FTD Value: $1,820,161.35, CAMP4 THERAPEUTICS CORP COM(DE
Sep 4, 2026
ftd
FTD: CAMP — 428,835 shares ($1.9M) failed to deliver
Settlement: 20260904, Price: $4.49, FTD Value: $1,925,469.15, CAMP4 THERAPEUTICS CORP COM(DE
Sep 1, 2026
other
CAMP4 to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopha
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.19 | $-0.23–$-0.15 | 65.3% | +0.0% | 1↑ 1↓ | $0.0B | 3 |
| Next Q | $-0.18 | $-0.20–$-0.16 | 22.4% | +0.0% | 2↑ 1↓ | $0.0B | 3 |
| Current FY | $-1.04 | $-1.27–$-0.71 | 37.0% | +0.0% | 1↑ 1↓ | $0.0B | 3 |
| Next FY | $-0.79 | $-0.87–$-0.70 | 23.5% | +0.0% | 2↑ 0↓ | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.186 | — |
| 7d ago | $-0.186 | — |
| 30d ago | $-0.186 | — |
| 60d ago | $-0.188 | +0.002 |
| 90d ago | $-0.188 | +0.002 |
Institutional ownership
Which big funds own CAMP (from quarterly 13F filings) and who is adding or trimming.
42 institutional holders with $104.5M total value (23,930,838 shares) as of 2026-Q2. Top holders: HUNTINGTON, Jupiter, FMR. Net buying activity: 11 institutions added/increased vs 4 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| HUNTINGTON NATIONAL BANK | 1 | $0.00 | 0.0% | — |
| Jupiter Topco LLC | 6,307,636 | $27.6M | 26.4% | — |
| FMR LLC | 4,904,339 | $21.4M | 20.5% | ADD +62.7% |
| BALYASNY ASSET MANAGEMENT L.P. | 2,575,724 | $11.3M | 10.8% | NEW |
| a16z Capital Management, L.L.C. | 2,125,339 | $9.3M | 8.9% | — |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,960,784 | $8.6M | 8.2% | — |
| BlackRock, Inc. | 1,644,134 | $7.2M | 6.9% | DOUBLED +260.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,533,489 | $6.7M | 6.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 795,651 | $3.5M | 3.3% | DOUBLED +107.8% |
| STATE STREET CORP | 362,300 | $1.6M | 1.5% | DOUBLED +146.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 456,371 | 1,644,134 | +260.3% | $7.2M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 382,821 | 795,651 | +107.8% | $3.5M |
| STATE STREET CORP | DOUBLED | 146,900 | 362,300 | +146.6% | $1.6M |
| NORTHERN TRUST CORP | DOUBLED | 70,666 | 248,673 | +251.9% | $1.1M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 78,345 | 241,393 | +208.1% | $1.1M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 20,000 | 96,660 | +383.3% | $422.4K |
| Bank of New York Mellon Corp | DOUBLED | 18,718 | 83,421 | +345.7% | $364.6K |
| MILLENNIUM MANAGEMENT LLC | TRIM | 85,918 | 43,903 | -48.9% | $191.9K |
| Hudson Bay Capital Management LP | TRIM | 48,511 | 18,661 | -61.5% | $81.5K |
| BANK OF AMERICA CORP /DE/ | TRIM | 31,196 | 17,773 | -43.0% | $77.7K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 24 transactions. Net $2.5M — $5.0M bought, $2.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Gold Kelly | Chief Financial Officer | BUY | 10,000 | $3.96 | $39.6K |
| Aug 27, 2026 | Schwab Andrew J. | Director | SELL | 400,000 | $4.04 | $1.6M |
| Aug 24, 2026 | Schwab Andrew J. | Director | SELL | 10 | $4.50 | $45.00 |
| Aug 21, 2026 | Schwab Andrew J. | Director | SELL | 32,018 | $4.50 | $144.1K |
| Aug 20, 2026 | Schwab Andrew J. | Director | SELL | 114,700 | $4.54 | $520.7K |
| Aug 19, 2026 | Tardiff Daniel | Chief Scientific Officer | SELL | 1,738 | $4.76 | $8.3K |
| Aug 19, 2026 | Schwab Andrew J. | Director | SELL | 45,147 | $4.76 | $214.9K |
| Aug 3, 2026 | Schwab Andrew J. | Director | AWARD | 3,179,558 | $1.53 | $4.9M |
| Aug 3, 2026 | 5AM Partners VI, LLC | 10%+ Owner | BUY | 3,179,558 | $1.53 | $4.9M |
| Aug 3, 2026 | Mandel-Brehm Josh | Chief Executive Officer | BUY | 6,551 | $1.65 | $10.8K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CAMP.
Shares short
992,712
Settlement Sep 15, 2026
Change vs prior
-16.4%
Semi-monthly cycle
Days to cover
3.6
At avg daily volume
Of shares outstanding
≈1.6%
Estimate — not % of float
All CAMP filing & press-release reports (13)
- PRESS-RELEASE reportSep 10, 2026
- CLUSTER reportSep 2, 2026
- CLUSTER reportAug 22, 2026
- EFFECT reportAug 13, 2026
- CLUSTER reportAug 6, 2026
- CLUSTER reportAug 5, 2026
- 8-K reportJul 27, 2026
- PRESS-RELEASE reportJun 19, 2026
- 8-K reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 14, 2026
- DEFA14A reportApr 23, 2026
- PRESS-RELEASE, 8-K reportMar 5, 2026